1713 related articles for article (PubMed ID: 33073988)
1. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
2. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
3. Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy.
Chen G; Chen Z; Wen D; Wang Z; Li H; Zeng Y; Dotti G; Wirz RE; Gu Z
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3687-3692. PubMed ID: 32029590
[TBL] [Abstract][Full Text] [Related]
4. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
7. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
[TBL] [Abstract][Full Text] [Related]
8. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
9. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
10. Bioinspired and Biomimetic Nanomedicines.
Chen Z; Wang Z; Gu Z
Acc Chem Res; 2019 May; 52(5):1255-1264. PubMed ID: 30977635
[TBL] [Abstract][Full Text] [Related]
11. Design of an Injectable Polypeptide Hydrogel Depot Containing the Immune Checkpoint Blocker Anti-PD-L1 and Doxorubicin to Enhance Antitumor Combination Therapy.
Shi Y; Li D; He C; Chen X
Macromol Biosci; 2021 Jun; 21(6):e2100049. PubMed ID: 33871152
[TBL] [Abstract][Full Text] [Related]
12. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
13. Janus Silica Nanoparticle-Based Tumor Microenvironment Modulator for Restoring Tumor Sensitivity to Programmed Cell Death Ligand 1 Immune Checkpoint Blockade Therapy.
Lin X; Li F; Guan J; Wang X; Yao C; Zeng Y; Liu X
ACS Nano; 2023 Aug; 17(15):14494-14507. PubMed ID: 37485850
[TBL] [Abstract][Full Text] [Related]
14. Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy.
Zhou L; Zhang P; Wang H; Wang D; Li Y
Acc Chem Res; 2020 Sep; 53(9):1761-1772. PubMed ID: 32819102
[TBL] [Abstract][Full Text] [Related]
15. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
[TBL] [Abstract][Full Text] [Related]
16. Platelets as platforms for inhibition of tumor recurrence post-physical therapy by delivery of anti-PD-L1 checkpoint antibody.
Han X; Chen J; Chu J; Liang C; Ma Q; Fan Q; Liu Z; Wang C
J Control Release; 2019 Jun; 304():233-241. PubMed ID: 31071371
[TBL] [Abstract][Full Text] [Related]
17. Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy.
Yang P; Lu C; Qin W; Chen M; Quan G; Liu H; Wang L; Bai X; Pan X; Wu C
Acta Biomater; 2020 Mar; 104():147-157. PubMed ID: 31904558
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Stimuli-Responsive Platforms for Cancer Immunotherapy.
Li L; Yang Z; Chen X
Acc Chem Res; 2020 Oct; 53(10):2044-2054. PubMed ID: 32877161
[TBL] [Abstract][Full Text] [Related]
19. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
20. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
